The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat

Neuropharmacology

Volumn 36, Issue 3, 1997, Pages 389-396

  Matto, V ^a   Harro, J ^b   Allikmets, L ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b Univ of TartuÜlikooli Str 18 ^*  (Estonia)

Author keywords

anxiety; benzodiazepines; cholecystokinin (CCK); cholecystokinin (CCK) receptors; elevated zero man.s.ze; exploratory behaviour

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR INVERSE STIMULATING AGENT; BUSPIRONE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; DIAZEPAM; FLUMAZENIL; LINTITRIPT; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; PD 135158; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; EXPLORATORY BEHAVIOR; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BEHAVIOR, ANIMAL; BENZODIAZEPINONES; DEVAZEPIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; HORMONE ANTAGONISTS; INDOLEACETIC ACIDS; MAZE LEARNING; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; THIAZOLES;

EID: 0030914578     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00011-7     Document Type: Article

References (51)

1. Andrews N., File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test. Eur. J. Pharmacol. 235:1993;109-112.
2. Artaiz I., Romero G., Zazpe A., Monge A., Caldero J.M., Roca J., Lasheras B., Del Rio J. The pharmacology of VA21B7: an atypical 5-HT4 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology. 117:1995;137-148.
3. Beinfeld M.C. (1995) Cholecystokinin/gastrin. In: Psychopharmacology. The Fourth Generation of Progress (Bloom F.E. and Kupfer D.J., Eds), pp. 585-594. Raven Press, New York.
4. Bickerdike M.J., Marsden C.A., Dourish C.T., Fletcher A. The influence of 5-hydroxytryptamine re-uptake blokade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur. J. Pharmacol. 271:1994;403-411.
5. Blanchard J.R., Yudko E.B., Rodgers R.J., Blanchard D.C. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav. Brain Res. 58:1993;155-165.
6. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiébot M.-H. Failure of the CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
7. Cole B.J., Hillmann M., Seidelmann D., Klewer M., Jones G.H. Effects of benzodiazepine receptor partial inverse agonists in the elevated plus-maze test of anxiety in the rat. Psychopharmacology. 121:1995;118-126.
8. Costall B., Domeney A.M., Hughes J., Kelly M.E., Naylor R.Y., Woodruff G.N. Anxiolytic effects of the CCK-B receptors. Neuropeptides. 19:1991;65-73.
9. Costall B., Kelly M.E., Naylor R.J., Onaivi E.S. Actions of buspirone in a putative model of anxiety in the mouse. J. Pharm. Pharmacol. 40((Suppl)):1988;494-500.
10. Dauge V., Steimes P., Derrien M., Beau N., Roques B.P., Feger J. CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens. Pharmacol. Biochem. Behav. 34:1989;157-163.
11. Dawson G.R., Crawford S.P., Collinson N., Iversen S.D., Tricklebank M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology. 118:1995;316-323.
12. B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology. 121:1995;109-117.
13. A receptors. Eur. J. Pharmacol. 232:1993;13-19.
14. Haefely W. Psychopharmacology of anxiety. Eur. Neuropsychopharmacol. 1:1991;89-95.
15. Handley S.L., McBlane J.W. An assessment of the elevated X-maze for studing anxiety and anxiety-modulating drugs. J. Pharmacol. Toxic. Meth. 29:1993;129-138.
16. Harro J. (1993a) Measurement of exploratory behaviour in rodents. In: Methods in Neurosciences, Vol. 14, pp. 359-377. Academic Press, San Diego.
17. Harro J. (1993b) Studies on the brain cholecystokinin receptors and behaviour. In: Comprehensive Summaries of Uppsala Dissertations from Faculty of Medicine, Vol. 421, pp. 6-32. Uppsala.
18. Harro J., Vasar E. Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour? Neurosci. Biobehav. Rev. 15:1993;473-477.
19. B receptors mediate the regulation of exploratory behaviour in the rat. Eur. J. Pharmacol. 193:1991;379-381.
20. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 14:1993;244-249.
21. Hendrie C.A., Neill J.C., Shepherd J.K., Dourish C.T. The effects of the CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol. Behav. 54:1993;689-693.
22. Hökfelt T. Neuropeptides in perspective: the last ten years. Neuron. 7:1991;867-879.
23. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodroff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natn. Acad. Sci. U.S.A. 87:1990;6728-6732.
24. Jackson H.C., Nutt D.J. Effects of benzodiazepine receptor inverse agonists on locomotor activity and exploration in mice. Eur. J. Pharmacol. 221:1992;199-203.
25. Kaesermann H.P. Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action. Psychopharmacology. 89:1986;31-37.
26. Kaesermann H.P., Dixon A.K. Further validation of the SAP test, a simple behavioural conflict test in mice. Psychopharmacology. 89:1986;S19.
27. Kobayashi S., Ohta M., Miyasaka K., Funakoshi A. Decrease in exploratory behaviour in naturally occurring cholecystokinin (CCK)-A receptor gene knockout rats. Neurosci. Lett. 214:1996;61-64.
28. Koszycki D., Cox B.J., Bradwejn J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am. J. Psychiat. 150:1993;1881-1883.
29. B antagonist, in panic disorder. Biol. Psychiat. 37:1995;462-466.
30. Lee C., Rodgers R.J. Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology. 30:1991;1263-1267.
31. Lines C., Challenor J., Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br. J. Clin. Pharmacol. 39:1995;235-242.
32. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 46:1990;321-340.
33. B receptors in behavioural and hormonal studies in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 349:1994;478-484.
34. Montgomery K.C. The relation between fear induced by novel stimulation and exploratory behaviour. J. Comp. Physiol. Psychol. 48:1955;254-260.
35. Moran T.H., Robinson P.H., Goldrich M.S., McHugh P.H. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362:1986;175-179.
36. Moser P.C. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology. 99:1989;48-53.
37. Nishimura H., Tanaka M., Tsuda A., Gondoh Y. Atypical anxiolytic profile of buspirone and a related drug, SM-3997, in a modified forced swim test employing straw suspension. Pharmacol. Biochem. Behav. 46:1993;647-651.
38. B receptor antagonist L-365,260. Eur. J. Pharmacol. 193:1991;203-208.
39. Pavlasevic S., Bednar I., Quereshi G.A., Södersten P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport. 5:1993;225-228.
40. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
41. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;525-529.
42. Pokk P., Zharkovsky A. The effects of drugs acting at GABA-benzodiazepine-barbiturate receptor complex on the behaviour of sleep-deprived mice. Pharmacol. Toxicol. 76:1995;23-28.
43. Poncelet M., Arnone M., Heaulme M., Gonalons N., Gueudet C., Santucci V., Thurneyssen O., Keane P., Gully D., Le Fur G., Soubriè P. Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;102-107.
44. Rataud J., Darche F., Piot O., Stutzmann J.M., Böhme G.A., Blanchard J.C. "Anxiolytic" effect of the CCK-antagonists on plus-maze behavior in mice. Brain Res. 584:1991;315-317.
45. Rex A., Barth T., Voigt J.-P., Domeney A.M., Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett. 172:1994;139-142.
46. Rodgers R.J. and Cole J.C. (1994) The elevated plus-maze: pharmacology, methodology, and ethology. In: Ethology and Psychopharmacology (Cooper S.J. and Hendrie C.A., Eds), pp. 9-44. Wiley Press Inc., N.Y.
47. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology. 113:1993;237-242.
48. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology. 116:1994;56-64.
49. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvment of the brain cholecystokinin B receptor in anxiety. Proc. Natn. Acad. Sci. U.S.A. 88:1991;1130-1133.
50. Wada T., Fukuda N. Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze. Psychopharmacology. 104:1991;444-450.
51. Weerts E.M., Tornatzky W., Miczek K.A. "Anxiolytic" and "anxiogenic" benzodiazepines and β-carbolines: effects on aggressive and social behaviour in rats and squirrel monkeys. Psychopharmacology. 110:1993;451-459.